Safari Flower Company, a wholly owned subsidiary of Aurora Cannabis, said it received European Union Good Manufacturing Practice (EU-GMP) certification for its Ontario facility. The certification is granted for a three-year term.
"We are incredibly proud to achieve the highest level of EU-GMP certification, which reinforces our position as a trusted cultivator and manufacturer of high-quality medical cannabis for international markets," said Brigitte Simons, CEO of Safari Flower Company, in a statement. "This milestone reflects the strong culture of compliance, quality and operational excellence embedded across our facility, and the trusted partnerships required to serve regulated supply chains. It further positions Safari to support the evolving needs of medical cannabis markets globally."
Safari's facility is a 59,000-square-foot cultivation and manufacturing site in the Niagara Region of Ontario, Canada with a history of EU-GMP accreditations and exporting operations. Aurora acquired the Safari Flower Company in April 2026 to provide incremental EU-GMP capacity to align with the company's existing global manufacturing network and to support supply of high-quality medical cannabis to international markets including Germany, Poland and the UK.
As international medical cannabis markets continue to evolve, EU-GMP certification remains a critical enabler of Safari's ability to serve regulated markets with confidence. The company is proud to be a trusted supplier of high-quality medical cannabis to markets that require rigorous quality, safety and compliance standards and to meet rapidly evolving patient demand.
